Insights

  • Date

  • Content Type

  • Reset

Case Study

Early phase modelling establishes opportunities and feasibility of ATMP for rare genetic disorder

3.02.23
A project consortium was launching an EU-funded clinical trial for a first-in-class advanced therapeutic medicinal

Blog

ICH’s viral safety guidelines catch up with the latest biotech innovations

1.02.23

By Sebastian Teitz, Ph.D

More than 25 years after adopting the first version of the guideline on the viral

White Paper

Science Huddle – SMALL DATA, BIG OUTCOMES

26.01.23
With the reach and impact of biopharma growing exponentially, experts in biotech and the evolving

Blog

The rise of Bayesian statistics in rare disease evidence gathering

16.01.23
Regulators are becoming more open to alternative data sources in the context of rare disease

We are now Cencora PharmaLex 

PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

Know more